BurgerFi Provides Fiscal Year 2023 Business Update
Sets Initial Business Outlook for Fiscal Year 2024 Focused on Five Key Strategic Initiatives FORT LAUDERDALE, Fla., Jan. 08, 2024 […]
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for Q4 2023 and between $64.9 million and […]
Fortrea Previews J.P. Morgan Healthcare Conference Updates
DURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today previewed […]
Relay Therapeutics Announces $30 Million Private Placement Financing
CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the […]
First Watch to Acquire 21 Franchise Restaurants in North Carolina
Transaction Represents Acquisition of Largest Franchisee Amends Credit Agreement to Support Acquisitive Growth BRADENTON, Fla., Jan. 08, 2024 (GLOBE […]
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted […]
Potbelly Corporation Reports Preliminary Results for Fourth Fiscal Quarter and Full Year 2023
Company to host a fireside chat and investor meetings at the 26thAnnual ICR Conference in Orlando, FL Monday, January 8, […]
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients
NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company […]
Five Below, Inc. Announces Holiday Sales Results for Quarter-To-Date Through January 6, 2024
Total Sales Increased 15.6%; Comparable Sales Increased 3.6% Reiterates Fourth Quarter and Full Year Fiscal 2023 Guidance, with Net Sales […]
Travere Therapeutics Provides Corporate Update and 2024 Outlook
Received 459 new patient start forms for FILSPARI®(sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI […]
